Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.20 million shs	N/A
ARWR Arrowhead Pharmaceuticals	$16.78 -0.7%	$15.45	$9.57 ▼ $30.41	$2.32B	0.93	1.55 million shs	800,545 shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
FOLD Amicus Therapeutics	$6.16 +3.4%	$6.17	$5.51 ▼ $12.65	$1.88B	0.51	3.17 million shs	3.12 million shs
PTCT PTC Therapeutics	$48.77 -0.8%	$48.21	$29.02 ▼ $58.38	$3.89B	0.5	863,724 shs	307,079 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+4.48%	-56.70%
ARWR Arrowhead Pharmaceuticals	0.00%	+4.35%	+1.94%	+57.12%	-33.07%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
FOLD Amicus Therapeutics	0.00%	+3.79%	+3.27%	-17.93%	-37.26%
PTCT PTC Therapeutics	0.00%	-2.14%	-5.72%	+12.79%	+57.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	2.8846 of 5 stars	3.1	0.0	0.0	4.7	0.0	2.5	1.3
ARWR Arrowhead Pharmaceuticals	3.9458 of 5 stars	3.4	2.0	0.0	3.4	2.8	2.5	0.0
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	3.7085 of 5 stars	3.4	1.0	0.0	4.3	0.6	0.0	1.9
PTCT PTC Therapeutics	4.3213 of 5 stars	4.3	1.0	0.0	4.4	1.5	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.51% Upside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	163.56% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.28% Upside

Current Analyst Ratings Breakdown

Latest DCPH, ARWR, FOLD, ALLK, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00
5/7/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $67.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
ARWR Arrowhead Pharmaceuticals	$3.55M	652.77	N/A	N/A	$1.54 per share	10.90
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
FOLD Amicus Therapeutics	$528.29M	3.59	N/A	N/A	$0.65 per share	9.47
PTCT PTC Therapeutics	$1.77B	2.18	N/A	N/A	($14.24) per share	-3.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	19.75	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.31	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.49	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)

Latest DCPH, ARWR, FOLD, ALLK, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
FOLD Amicus Therapeutics	2.02	3.34	2.47
PTCT PTC Therapeutics	N/A	3.89	3.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
ARWR Arrowhead Pharmaceuticals	62.61%
DCPH Deciphera Pharmaceuticals	70.96%
FOLD Amicus Therapeutics	N/A
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
ARWR Arrowhead Pharmaceuticals	4.30%
DCPH Deciphera Pharmaceuticals	4.67%
FOLD Amicus Therapeutics	2.20%
PTCT PTC Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable

DCPH, ARWR, FOLD, ALLK, and PTCT Headlines

Recent News About These Companies

Wealth Enhancement Advisory Services LLC Acquires New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)

July 5 at 3:21 AM | marketbeat.com

PTCT | PTC Therapeutics Inc. Annual Cash Flow Statement - MarketWatch

July 4 at 4:31 AM | marketwatch.com

Cantor Fitzgerald Has Weak Estimate for PTCT FY2026 Earnings

July 4 at 2:07 AM | americanbankingnews.com

FY2025 EPS Estimates for PTCT Decreased by Cantor Fitzgerald

July 3 at 2:38 AM | americanbankingnews.com

FY2026 EPS Estimates for PTCT Cut by Cantor Fitzgerald

July 2, 2025 | marketbeat.com

Cantor Fitzgerald Has Weak Estimate for PTCT FY2025 Earnings

July 1, 2025 | marketbeat.com

PTC Therapeutics Inc. (PTCT) Stock Price Today - WSJ

June 30, 2025 | wsj.com

PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

June 30, 2025 | msn.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts

June 27, 2025 | americanbankingnews.com

PTC Therapeutics Gets Marketing Authorization For Sephience In EU To Treat Phenylketonuria - Nasdaq

June 24, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Perspective Therapeutics (CATX) and PTC Therapeutics (PTCT)

June 24, 2025 | theglobeandmail.com

PTC Therapeutics Inc News (PTCT) - Investing.com

June 24, 2025 | investing.com

PTC Therapeutics’ Sephience gets European marketing authorization to treat children and adults living with phenylketonuria

June 24, 2025 | pharmabiz.comP

PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

June 24, 2025 | prnewswire.com

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

June 23, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 22, 2025 | prnewswire.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from Analysts

June 22, 2025 | marketbeat.com

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

June 20, 2025 | msn.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 19, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 17, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, ARWR, FOLD, ALLK, and PTCT Company Descriptions

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)

As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.78 -0.12 (-0.71%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$16.78 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.21 (+3.45%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$6.08 -0.08 (-1.22%)

As of 07/3/2025 04:51 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

PTC Therapeutics NASDAQ:PTCT

$48.77 -0.38 (-0.77%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$48.77 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time